1. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long- term outcomes 
Aki Juhani Käräjämäki, Risto Bloigu, Heikki Kauma, Y. Antero Kesäniemi, Olli-Pekka Koivurova, Juha Perkiömäki, Heikki Huikuri, Olavi Ukkola 
Metabolism - Clinical and Experimental 
Volume 66, Pages (January 2017)
DOI: /j.metabol
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Fig. 1
The cumulative survival in different study groups as Kaplan–Meier trend. Abbreviations: NAFLD, non-alcoholic fatty liver disease; MetS, metabolic syndrome.
Metabolism - Clinical and Experimental  , 55-63DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Fig. 2
The prevalences of new diabetics in different study groups. p for trend < The p-values were statistically significant (*) between those with both diseases and NAFLD only (p=0.029) or without either condition (p<0.001) and MetS only and without either condition (**, p<0.001). Abbreviations: NAFLD, non-alcoholic fatty liver disease; MetS, metabolic syndrome.
Metabolism - Clinical and Experimental  , 55-63DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Fig. 3
The mean changes of left ventricular mass index according to the study groups after more than 20years' follow-up. p for trend < The p-values were statistically significant between the groups with both diseases and without either condition (*, p=0.001) and MetS only and without either condition (**, p=0.006). Abbreviations: LVMI, left ventricular mass index; NAFLD, non-alcoholic fatty liver disease; MetS, metabolic syndrome.
Metabolism - Clinical and Experimental  , 55-63DOI: ( /j.metabol )
Copyright © 2016 Elsevier Inc. Terms and Conditions